Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
14 Machi 2021 18:59:12
Aztreonam na ujauzito
Hakuna taarifa inayoeleza matumizi a dawa hii katika ujauzito kwenye dozi inayotakiwa kwa wajawazi
Ushauri dhidi ya matumizi kwa mama mjamzito
Hakuna (zipo chache) taarifa za binadamu- taarifa za wanyama zinaonyesha kuwepo hatari kidogo
Hakuna (zipo chache) taarifa za binadamu- taarifa za wanyama zinaonyesha kuwepo hatari kidogo ina maana gani?
Inawezekana kuwa hakuna taarifa za zoefu wa matumizi ya dawa hii au taarifa za binadamu wajawazito wachache waliotumia dawa hii zimeonyesha kutohusiana kuwa sumu kwa kichangawa tumboni kuweza kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo endapo itatumika. Dawa haileti sumu kwenye uumbaji wa kijusi( kwenye dozi ambayo haikusababisha sumu kwa mama) kwenye jamii zote za wanyama waliofanyiwa tafiti kwenye dozi ambayo ni sawa au pungufu ya mara kumi ya ile ya binadamu, dozi inayotolewa kuendana na jumla ya eneo la mwili
Ushauri dhidi ya matumizi kwa mama anayenyonyesha
Inapatana na ujauzito
Inapatana na ujauzito, ina maana gani?
Kiasi kidogo cha dawa hii kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Dawa hii haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:21:36
Rejea za mada hii
1. Furuhashi T, et al. Toxicity study of azthreonam: fertility study in rats.Chemotherapy 1985;33:190–202. As cited in Shepard TH. Catalog of Teratogenic Agents .6th ed. Baltimore, MD: Johns Hopkins University Press, 1989:66.
2. Furuhashi T, et al. Toxicity study on azthreonam: teratology study in rats. Chemotherapy 1985;33:203–18. As cited in Shepard TH. Catalog of Teratogenic Agents . 6th ed. Baltimore, MD: Johns Hopkins University Press, 1989:66.
3. Furuhashi T,et al. Toxicity study on azthreonam: perinatal and postnatal study in rats. Chemotherapy 1985;33:219–31. As cited in Shepard TH. Catalog of Teratogenic Agents . 6th ed. Baltimore, MD: Johns Hopkins University Press, 1989:66.
4. Singhvi SM, et al. Distribution of aztreonam into fetuses and milk of rats. Antimicrob Agents Chemother 1984;26:132–5.
5. Product information. Azactam. E. R. Squibb & Sons, 1994.
6. Hayashi R, Devlin RG, Frantz M, Stern M. Concentration of aztreonam in body fluids in mid-pregnancy (abstract). Clin Pharmacol Ther 1984;35:246.
7. Ito K, et al. Pharmacokinetic and clinical studies on aztreonam in the perinatal period. Jpn J Antibiot 1990;43:719–26
8. Matsuda S, et al. Transplacental transfer and clinical application of aztreonam. Jpn J Antibiot 1990;43:700–5.
9. Obata I, et al. Pharmacokinetic study of aztreonam transfer from mother to fetus. Jpn J Antibiot 1990;43:70–80.
10. Cho N, et al. Studies on aztreonam in the perinatal period. Jpn J Antibiot 1990;43:706–18.
11. Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. Dev Pharmacol Ther 1987;10:174–98.
12. Cook V, et al. The pharmacokinetics of aztreonam during pregnancy(abstract). Am J Obstet Gynecol 1994;170:420.
13. Fleiss PM, et al. Aztreonam in human serum and breast milk. Br J Clin Pharmacol 1985;19:509–11.
14. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89.